{"id":924165,"date":"2026-01-06T12:14:55","date_gmt":"2026-01-06T17:14:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/"},"modified":"2026-01-06T12:14:55","modified_gmt":"2026-01-06T17:14:55","slug":"spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/","title":{"rendered":"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer"},"content":{"rendered":"
\n

ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma\u2122, a late-stage biopharmaceutical company, today announced the appointment of Jean-Fr\u00e9d\u00e9ric Viret, Ph.D., as the company\u2019s Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization.<\/p>\n

\u201cWe are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clinical development program for the BIM-IOL system,\u201d said Patrick Mooney, Chief\u00a0Executive Officer of SpyGlass Pharma. \u201cJean\u2019s deep experience in driving successful late-stage development investment while advancing clinical pipelines will be instrumental at this point in the company\u2019s journey.\u201d<\/p>\n

Dr. Viret is a seasoned CFO with a proven track record of creating substantial value for companies through the development and commercialization phases and building strong finance and accounting functions. His most recent roles include serving as CFO of NGM Biopharmaceuticals, Inc. and Blade Therapeutics, Inc. Before Blade, Dr. Viret was CFO at Coherus BioSciences, Inc. (NASDAQ: CHRS), now Coherus Oncology, a commercial-stage biopharmaceutical company that he joined in 2014. Additionally, he has prior experience in CFO roles at several public and privately held biopharmaceutical and diagnostics companies. He started his business career at PwC.<\/p>\n

In addition to a Ph.D. in Plant Molecular Biology from Universit\u00e9 Louis Pasteur (Strasbourg,\u00a0France), Dr. Viret has a B.S. in Engineering from the Institut National Polytechnique de\u00a0Lorraine and an M.B.A. from Cornell University. He was a visiting fellow at Harvard\u00a0University and a postdoctoral fellow at the Massachusetts Institute of Technology.<\/p>\n

\u201cI am excited to join SpyGlass at such a pivotal moment for the company following its\u00a0positive preliminary Phase I\/II results of the BIM-IOL System in patients with open-angle\u00a0glaucoma and ocular hypertension undergoing cataract surgery,\u201d said Dr. Viret. \u201cAnchored\u00a0by the BIM-IOL System, SpyGlass is poised to revolutionize treatment across a range of\u00a0chronic eye conditions by addressing the massive burden of patient adherence. I look\u00a0forward to working with SpyGlass leadership to build upon its strong foundation to\u00a0accelerate value generation and investment in both the BIM-IOL System and its robust\u00a0pipeline.\u201d<\/p>\n

\n ABOUT SPYGLASS PHARMA<\/strong>\n <\/p>\n

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company\u2019s mission is to redefine the management of these conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.<\/p>\n

The SpyGlass Platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.<\/p>\n

The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve\u00a0the lack of ophthalmic innovations that capitalize on durable treatment options. The\u00a0SpyGlass Platform was originally developed in the Sue Anschutz-Rodgers Eye Center of the\u00a0University of Colorado School of Medicine.<\/p>\n

For more information, visit\u00a0www.spyglasspharma.com<\/a>.<\/p>\n

\n Media Contact:<\/strong>
\n
Nami Surendranath
+1 (212) 418-8981
NSurendranath@dnacommunications.com<\/a><\/p>\n

Investor Contact:<\/strong>
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
investors@spyglasspharma.com<\/a><\/p>\n

A photo accompanying this announcement is available at https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/baa9a435-20ec-4f91-b8e0-dde6b1556dc1<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma\u2122, a late-stage biopharmaceutical company, today announced the appointment of Jean-Fr\u00e9d\u00e9ric Viret, Ph.D., as the company\u2019s Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. \u201cWe are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clinical development program for the BIM-IOL system,\u201d said Patrick Mooney, Chief\u00a0Executive Officer of SpyGlass Pharma. \u201cJean\u2019s deep experience in driving successful late-stage development investment while … <\/p>\n

Continue reading “SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-924165","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma\u2122, a late-stage biopharmaceutical company, today announced the appointment of Jean-Fr\u00e9d\u00e9ric Viret, Ph.D., as the company\u2019s Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. \u201cWe are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clinical development program for the BIM-IOL system,\u201d said Patrick Mooney, Chief\u00a0Executive Officer of SpyGlass Pharma. \u201cJean\u2019s deep experience in driving successful late-stage development investment while … Continue reading "SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T17:14:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer\",\"datePublished\":\"2026-01-06T17:14:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/\"},\"wordCount\":599,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/\",\"name\":\"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=\",\"datePublished\":\"2026-01-06T17:14:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer - Market Newsdesk","og_description":"ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma\u2122, a late-stage biopharmaceutical company, today announced the appointment of Jean-Fr\u00e9d\u00e9ric Viret, Ph.D., as the company\u2019s Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. \u201cWe are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clinical development program for the BIM-IOL system,\u201d said Patrick Mooney, Chief\u00a0Executive Officer of SpyGlass Pharma. \u201cJean\u2019s deep experience in driving successful late-stage development investment while … Continue reading \"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-06T17:14:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer","datePublished":"2026-01-06T17:14:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/"},"wordCount":599,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/","name":"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=","datePublished":"2026-01-06T17:14:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDIyMyM3MzQ1MjQ5IzIyNTI0NjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spyglass-pharma-appoints-jean-frederic-viret-as-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SpyGlass Pharma Appoints Jean-Fr\u00e9d\u00e9ric Viret as Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=924165"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924165\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=924165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=924165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=924165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}